About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Advertisement

Medindia » Health Press Releases A-Z

FDA Issues Complete Response Letter for Ceftobiprole

Advertisement

CONTACTS:
Media: Ernie Knewitz, 908-927-2953 or Amy Firsching, 908-218-7583
Investor Relations: Louise Mehrotra, 732-524-6491

Sponsored Post and Backlink Submission

Latest Press Release on Drug News

Happy Fruit Redefines Wellness with THCV-Infused Gummies: A Breakthrough in Cannabinoid Innovation and Metabolic Supplements

Unlocking the Power of THCV: Happy Fruit's New Gummies Suppress Appetites and Provide Metabolic Support * OCEANSIDE, Calif. , April 18, 2024 /PRNewswire/ -- Happy Fruit ...

41st International Conference on Drug Discovery and Drug delivery system

On behalf of the organizing committee its great pleasure to invite to all attendees of the "41st International Conference on Drug Discovery and Drug Delivery System" taking place on November...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), hig...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

CHICAGO , April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has bee...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close